Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Yuexin Xu"'
Publikováno v:
Current Pharmaceutical Design. 26:3171-3186
Background: Metastatic colorectal cancer (mCRC) is one of the most common and deadly cancers worldwide. For most patients diagnosed with mCRC and managed with 5-fluorouracil (5-FU)/leucovorin plus oxaliplatin (FOLFOX), the median survival time is sti
Autor:
Yuexin Xu, Xiaoxuan Du
Publikováno v:
Experimental and Therapeutic Medicine
Application of dexmedetomidine-assisted intravertebral anesthesia for elderly patients with hip replacement and its influences on T-lymphocyte subsets in peripheral blood were assessed. Eighty-six patients undergoing intravertebral anesthesia in hip
Autor:
Benjamin Diamond, Edgar Gonzalez-Kozlova, Edus H. Warren, David G. Coffey, Sacha Gnjatic, Ola Landgren, Dickran Kazandjian, Damian J. Green, Trevor J. Pugh, Alexander M. Lesokhin, Francesco Maura, Yuexin Xu, Javier Diaz-Mejia, Ping Luo, Eric L. Smith, Yong Zhang, Hearn Jay Cho
Publikováno v:
Blood. 138:329-329
Background: The progression of multiple myeloma (MM) during ongoing therapy is driven by a complex interplay between tumor cells and their surrounding immune microenvironment. We were motivated to conduct a comprehensive and orthogonal investigation
Autor:
Yifang Shui, Jianlei Lu, Shuang Qu, Yuexin Xu, Shiyang Pan, Changyan Ma, Yucui Jin, Li Chen, Bing Yao, Kaikai Shi
Publikováno v:
Oncotarget
Lu, J, Qu, S, Yao, B, Xu, Y, Jin, Y, Shi, K, Shui, Y, Pan, S, Chen, L & Ma, C 2016, ' Osterix acetylation at K307 and K312 enhances its transcriptional activity and is required for osteoblast differentiation ', Oncotarget, vol. 7, no. 25, pp. 37471-37486 . https://doi.org/10.18632/oncotarget.9650
Lu, J, Qu, S, Yao, B, Xu, Y, Jin, Y, Shi, K, Shui, Y, Pan, S, Chen, L & Ma, C 2016, ' Osterix acetylation at K307 and K312 enhances its transcriptional activity and is required for osteoblast differentiation ', Oncotarget, vol. 7, no. 25, pp. 37471-37486 . https://doi.org/10.18632/oncotarget.9650
// Jianlei Lu 1,* , Shuang Qu 1,* , Bing Yao 1,* , Yuexin Xu 1 , Yucui Jin 1 , Kaikai Shi 1 , Yifang Shui 1 , Shiyang Pan 2 , Li Chen 3 and Changyan Ma 1 1 Department of Developmental Genetics, Nanjing Medical University, Nanjing, P.R. China 2 Depart
Autor:
Damian J. Green, Trevor J. Pugh, Ola Landgren, Yuexin Xu, David G. Coffey, Edus H. Warren, Dickran Kazandjian, Sacha Gnjatic
Publikováno v:
Blood. 134:4367-4367
Introduction: Maintenance therapy with the immunomodulatory drug (IMiD) lenalidomide improves progression-free survival (PFS) and overall survival among patients with multiple myeloma (MM). It has been suggested that IMiDs enhance immune-mediated ant